![]() |
The ASCO Post, 2013:
|
![]() |
Shortages - Dr Len's Cancer Blog: FDA: The Quality Problems Causing The Drug Shortage Were Not News To Those Making The Medicines |
![]() |
Shortages - Medscape: Stopgaps Avert Methotrexate and Doxil Shortages -- For Now |
![]() |
Shortages - NYTimes: Shipments From Abroad to Help Ease Shortage of Two Cancer Drugs |
![]() |
Denialism blog: Drug Shortages Reveal the Free Market is Failing Our Sickest Patients |
![]() |
Shortage - ASH: American Society of Hematology statement on critical methotrexate drug shortage |
![]() |
Shortages - Dr Len's Cancer Blog: The Cancer Drug Shortage: Patients And Families Deserve Better |
![]() |
Shortages - Medscape: Methotrexate Crisis: Rationing of Resources is 'Unacceptable' |
![]() |
Shortages - MSNBC: Amid shortages, rules force hospitals to trash scarce drugs |
![]() |
Shortages - PBS News Hour: What's Causing a Shortage of Pediatric Cancer Drugs? |
![]() |
Shortages - WSJ: Sebelius Says Leukemia-Drug Shortage Will Be Resolved Within Two Weeks
|
![]() |
MSNBC: Drug Shortages hits all time high |
![]() |
ASCO Post - Chemotherapy Drug Shortages: A Preventable Human Disaster
|
![]() |
NEJM: The Shortage of Essential Chemotherapy Drugs in the United States |
![]() |
NY Times: Obama Tries to Speed Response to Shortages in Vital Medicines |
![]() |
The Marietta Daily Journal: The cruelest cut: Cancer practice says lower reimbursement would devastate patient care |
![]() |
Medscape: Private Oncology Practices Blamed for Ongoing Drug Shortages |
![]() |
Washington Post: Cancer treatment costs can be prohibitive, even with insurance |
![]() |
PharmaTimes: US drug shortages soar, Congressman probes "grey" marketeers |
![]() |
PharmaTimes: US drug shortages soar, Congressman probes "grey" marketeers |
![]() |
NPR transcript and audio: Shortages Lead Doctors To Ration Critical Drugs |
![]() |
USA Today: A life and death wait for cancer medications in short supply |
![]() |
Science-Based Medicine:
|
![]() |
Fixing the Drug Shortage:
|
![]() |
Cancer Drug Shortages Are Placing Patients at Risk - Shortages are approaching crisis point Medscape.com |
![]() |
Oncology drugs currently experiencing shortages: NCCN.org |
![]() |
Oncology Times:
|
![]() |
NY Times:
|
![]() |
Comprehensive list of drug shortages johalimedical.com |
![]() |
NY Times:
|
![]() |
Susan Krivacic's Letter to
|
Information on Blood Cancer drugs
copied 6/10/2011 from FDA.gov
Bleomycin Injection (updated 6/3/2011)
Company/Products | Reason | Related Information |
---|---|---|
APP 1-888-386-1300 15 unit vial (NDC 63323-0136-10), 30 unit vial (NDC 63323-0137-20) |
Increased demand |
APP is currently back-ordered on all presentations of Bleomycin for Injection at this time. APP is anticipating batch releases to resume in the first quarter of 2011. |
Teva Pharmaceuticals 1-800-545-8800 |
Manufacturing delays | 15 unit vials (NDC 00703-3154-01) and 30 unit vials (NDC 00703-3155-01) are now available and the company is reviewing orders prior to shipping. |
Bedford 1-800-562-4797 15 unit vial (NDC 55390-0005-01), 30 unit vial (NDC 55390-0006-01) |
Product discontinued | Bedford currently has all presentations discontinued. |
Hospira Inc. Customer Service: 1-877-946-7747 15 unit vial (NDC 61703-0332-18) 30 unit vial (NDC 61703-0323-22) |
Higher than anticipated market demand. |
Products 15 unit vial (NDC 61703-332-18) and 30 unit vial (NDC 61703-323-22): next release in June.
Please check with your wholesaler for available inventory. |
Daunorubicin hydrochloride solution for injection (updated 5/10/2011)
Company/Products | Reason | Related Information |
---|---|---|
Teva Pharmaceuticals 1-800-545-8800 5 mg/mL, 4 mL single-dose vial (NDC 00703-5233-13) |
Manufacturing issues | Teva has daunorubicin solution for injection on back order and estimates a release date of August, 2011. |
Bedford Customer Service 1-800-562-4797 5 mg/mL, 4 mL single-dose vial (NDC 55390-0108-10), 10 mL single-dose vial (NDC 55390-0108-01) Cerubidine lyophilized powder for injection, 20 mg single-dose vial, package of 10 (NDC 55390-0281-10) |
Manufacturing delays | Bedford will release 20 mg lyophilized powder for injection in early May. Bedford will release daunorubicin solution for injection, 20 mg and 50 mg, in the next 3-months. |
Doxorubicin (adriamycin) lyophilized powder (updated 5/10/2011)
Company/Products | Reason | Related Information |
---|---|---|
Bedford 10 mg vials (NDC 55390-0231-01) 20 mg vials (NDC 55390-0232-10) 50 mg vial (NDC 55390-0233-01) |
Manufacturing delays | Bedford anticipates release of all presentations in the next 6-months. |
Doxorubicin Solution for Injection (updated 5/10/2011)
Company/Products | Reason | Related Information |
---|---|---|
APP 1-888-386-1300 APP Product Availability Information8 ![]() |
Increased demand | APP is releasing the 2mg/ml 100 ml vials (NDC 63323-0101-61), the 2mg/ml 25 ml vials (NDC 63323-0883-30), and the 2mg/ml 5 ml vials (NDC 63323-0883-05) as it becomes available. |
Teva Pharmaceuticals 1-800-545-8800 |
Manufacturing delays | Teva is releasing all strengths on allocation: Doxorubicin solution for injection, 2 mg/mL 5 mL vial (NDC 00703-5043-03) 25 mL vial (NDC 00703-5046-01) 100 mL vial (NDC 00703-5040-01). |
Bedford 1-800-562-4797 |
Manufacturing delays | Bedford anticipates release of the 50mg presentation in the next 3months and release of the 10 mg, 25 mg, and 100 mg solutions in the next 6-months. |
Etoposide solution for injection (updated 5/10/2011)
Company/Products | Reason | Related Information |
---|---|---|
Bedford 1-800-562-4797 |
Increased demand | Bedford anticipates release of 500 mg product in early May, 1g in the next 3-months, and 100 mg in the next 6-months. |
Teva Pharmaceuticals 1-800-545-8800 |
Manufacturing delays | Teva has Toposar 20 mg/mL solution for injection 5 mL vials (NDC 00703-5653-01) vials availalbe. The 25 mL and 50 mL vials are on back order. |
APP 1-888-386-1300 |
Manufacturing delays | APP is releasing all etoposide solution for injection 20 mg/mL presentations as they become available. |
BMS Customer Service 1-800-426-7644 |
Increased demand | BMS has available Etopophos 100 mg powder for injection (NDC 00015-3404-20). |
Thiotepa for Injection (updated 5/13/2011)
Company/Products | Reason | Related Information |
---|---|---|
Bedford Laboratories Customer Service 1-800-562-4797 15 mg/mL vial (NDC 55390-0030-10) |
Manufacturing delays | Bedford anticipates release mid-May. |
Adienne | Adienne, in conjunction with the FDA, is initiating a temporary importation of Thiotepa for injection, to the United States market. Please see the Dear Healthcare Professional Letter (PDF - 1MB)25 for information about emergency supplies that are now available to help address the shortage. |
Vincristine Sulfate Injection (updated 6/3/2011)
Company/Products | Reason | Related Information |
---|---|---|
Hospira Inc. Customer Service: 1-877-946-7747 1 mg/mL; 1 mL vial (NDC 61703-309-06) (NDC 61703-309-16) |
Higher than anticipated market demand. |
Product 1 mg/mL; 1 mL vial (NDC 61703-309-06): ample levels of inventory to support market demand.
Product 1 mg/mL; 2 mL vial (NDC 61703-309-16): next release in June, with ample levels of inventory to support market demand achieved by July.
Please check with your wholesaler for available inventory. |
Teva Pharmaceuticals 1-800-545-8800 |
Teva has 1 mg/mL 1 mL vial (NDC 00703-4402-11) and 2 mL vial (NDC 00703-4412-11) now available and is shipping to wholesalers. |